Suppr超能文献

影响 5 个或以上脑转移瘤患者立体定向放射外科治疗效果的因素。

Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases.

机构信息

Centre hospitalier universitaire de Sherbrooke, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC.

出版信息

Curr Oncol. 2019 Feb;26(1):e64-e69. doi: 10.3747/co.25.4244. Epub 2019 Feb 1.

Abstract

BACKGROUND

Stereotactic radiosurgery (srs) for patients with 5 or more brain metastases (bmets) is a matter of debate. We report our results with that approach and the factors influencing outcome.

METHODS

In the 103 patients who underwent srs for the treatment of 5 or more bmets, primary histology was non-small-cell lung cancer (57% of patients). All patients were grouped by Karnofsky performance status and recursive partitioning analysis (rpa) classification. In our cohort, 72% of patients had uncontrolled extracranial disease, and 28% had stable or responding systemic disease. Previous irradiation for 1-4 bmets had been given to 56 patients (54%). The mean number of treated bmets was 7 (range: 5-19), and the median cumulative bmets volume was 2 cm (range: 0.06-28 cm).

RESULTS

Multivariate analyses showed that stable extracranial disease ( < 0.001) and rpa ( = 0.022) were independent prognostic factors for overall survival (os). Moreover, a cumulative treated bmets volume of less than 6 cm (adjusted hazard ratio: 2.54; = 0.006; 95% confidence interval: 1.30 to 4.99) was associated with better os. The total number of bmets had no effect on survival ( = 0.206). No variable was found to be predictive of local control. The rpa was significant ( = 0.027) in terms of distant recurrence.

CONCLUSIONS

Our study suggests that srs is a reasonable option for the management of patients with 5 or more bmets, especially with a cumulative treatment volume of less than 6 cm.

摘要

背景

对于 5 个或以上脑转移瘤(BMETs)的患者,立体定向放射外科(SRS)的应用存在争议。我们报告了采用该方法治疗 5 个或以上 BMETs 的结果以及影响疗效的因素。

方法

103 例接受 SRS 治疗 5 个或以上 BMETs 的患者中,原发性组织学为非小细胞肺癌(57%的患者)。所有患者按 Karnofsky 表现状态和递归分区分析(RPA)分类分组。在我们的队列中,72%的患者有不可控制的颅外疾病,28%的患者有稳定或应答的全身疾病。56 例(54%)患者之前接受过 1-4 个 BMETs 的放疗。治疗的 BMETs 数量中位数为 7(范围:5-19),累积 BMETs 体积中位数为 2cm(范围:0.06-28cm)。

结果

多变量分析表明,稳定的颅外疾病(<0.001)和 RPA(=0.022)是总生存(OS)的独立预后因素。此外,累积治疗 BMETs 体积小于 6cm(调整后的危险比:2.54;=0.006;95%置信区间:1.30 至 4.99)与更好的 OS 相关。BMETs 的总数对生存没有影响(=0.206)。没有变量可以预测局部控制。RPA 对远处复发具有显著意义(=0.027)。

结论

我们的研究表明,SRS 是治疗 5 个或以上 BMETs 的合理选择,尤其是累积治疗体积小于 6cm 的患者。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验